Searching for Solutions

Dr. Yelena Lugin, PharmD, BCPP, provides tips on telehealth services.

National Volunteer Week coincides with AAPP 2026 in Seattle but we don’t want that to detract from celebrating our amazing volunteers. So, we are saying our thank yous a week early. Every year, approximately 215 members contribute their time and talent to AAPP as members of committees, the Board of Directors, task forces, and editorial boards. This doesn’t include the countless other members who write, speak, represent AAPP at meetings, and much more.

AAPP joined numerous other Mental Health Liaison Group member organizations in expressing strong coalition support for the introduction and swift passage of legislation to remove the 190-day lifetime limit on inpatient psychiatric treatment for Medicare beneficiaries.

The xylazine toolkit, intended to highlight the evidence base available and strategies of clinical decision making, was recently updated by AAPP member Sarah Thomason to include sections on regulatory status, laboratory testing and wound care.

In this year’s report, OCP celebrates its 30th anniversary, showcasing the Office’s contributions to the evolution of clinical pharmacology into a foundational pillar of drug development and regulatory review by enhancing efficacy and safety evaluations through rigorous, collaborative, and state-of-the-art approaches.

US adults likely have heterogenous views on addiction, and more research is needed to further understand how US adults conceptualize addiction.

In this study, SROM for OUD was associated with slightly higher treatment discontinuation risk than methadone but similar mortality risk, suggesting either medication may be appropriate alongside measures to support retention.

Stimulant-induced psychosis occurs in both therapeutic and nontherapeutic contexts but at vastly different prevalence rates.

While both PWUF and clinicians identified precipitated withdrawal as a major concern when initiating buprenorphine, it was just one of many barriers.

This paper provides an overview of SED, including the role of functional impairment in identifying youth with SED and the important developmental considerations.

This report provides a guide to publicly accessible data sources to support research and improve data-driven decision-making for individuals dually eligible for Medicaid and Medicare.

State Medicaid expansions from 2017 to 2023 increased access to medication treatment for opioid use disorder at a time when fatal overdoses were continuing to climb, researchers wrote in JAMA Network Open. That means coverage expansions can significantly affect uptake of addiction medicine like buprenorphine. The findings could be important for state governments wrestling with reductions in federal Medicaid spending.

The CURESZ Foundation (Comprehensive Understanding via Research and Education into SchiZophrenia) founded by Bethany Yeiser and Dr. Henry Nasarallah has assembled a Clozapine in Schizophrenia Expert Panel (CLOSZE). The goal is to assist individuals living with schizophrenia and/or caregivers in finding a clinician who can assist them in trying clozapine. AAPP encourages psychiatric pharmacists to sign up for the registry so that patients/caregivers can outreach to establish ongoing care.

Collegiate Chapter Impact Grant recipients will share their grant-funded projects during the Collegiate Chapter Meeting on Sunday, 4/19! Join chapter representatives in the Cedar Ballroom from 4:45-5:15 PM Pacific Time. Presentations will not be livestreamed; however, they will be recorded and posted for those unable to attend live. Thank you to our donors for helping us continue this important grant program with your monetary gifts.

Thanks to generous AAPP Foundation donors and the AAPP Past Presidents' Destiny Fund, 33 PharmD students were awarded full, in-person student registration grants to AAPP 2026! Congratulations to each of the recipients and enjoy your time in Seattle!